key: cord-0772598-lu7jc46c
authors: Bogani, Giorgio; Raspagliesi, Francesco; Ditto, Antonino; de la Fuente, José
title: The Adoption of Viral Capsid-Derived Virus-Like Particles (VLPs) for Disease Prevention and Treatments
date: 2020-08-02
journal: Vaccines (Basel)
DOI: 10.3390/vaccines8030432
sha: b9f735e57abe55e6bc4ba6c91c25e3fe55c9d0ba
doc_id: 772598
cord_uid: lu7jc46c

In the present paper, Mohosen et al. [1] reviewed the evidence of the interaction between virus-like particles (VLPs) and the innate immune system. [...].

In the present paper, Mohosen et al. [1] reviewed the evidence of the interaction between virus-like particles (VLPs) and the innate immune system. VLPs are molecules resembling viruses. VLPs do not contain the genetic material of virus, and they are not infective. VLPs are an important class of nanoparticles characterized by a number of noteworthy applications into research and clinical practice. Generally, VLPs are adopted as vaccines. VLPs contain repetitive, high-density displays of viral surface proteins that present conformational viral epitopes that can elicit strong T cell and B cell immune responses [2] . Moreover, VLPs would be adopted for delivery of genes and other therapeutic agents [3] . As indicated by Mohosen et al. [1] , size and surface geometry are the two main factors driving the interaction between VLPs and the humoral immune system. Additionally, the highly repetitive surface of VLPs is on the basis of the interaction with the innate immune system [4] . Another important feature in the field of VLPs, was the adoption of lipoparticles. Lipoparticles are purified and homogeneous VLPs that are engineered to contain the intact membrane proteins and are useful for delivering target therapies [5] . Furthermore, VLPs displaying the alpha-Gal carbohydrate, a molecule eliciting protective immune response against multiple pathogens [6] , have shown protection against Leishmaniosis [7] . To date, there is an emerging need to develop and implement VLPs. Engineered VLPs have a role in developing new, safe vaccines and delivering (as vector) components into the cells and their membranes. Understanding the mechanisms of interaction between VLPs and the immune system would be of paramount importance. Using tumor-associated antigens, the VLPs would also be adopted for the design of anticancer vaccines (therapeutic vaccines). To date, the growing adoption of VLPs in preclinical and clinical studies aimed to bridge the gap of preventing and treating diseases, including cancer. Prophylactic vaccines against human papillomavirus (HPV) are based on VLPs. These vaccines prevent preneoplastic lesions of the female and male lower genital tract and the head and neck district [2] . Currently, some of the vaccine projects on phase I and phase II clinical trials for the control of COVID-19 are based on VLPs [8, 9] , thus supporting the potential for these interventions. Similarly, ongoing trials on therapeutic vaccines are based on VLPs. One of these therapeutic vaccines include the use of VLP-encapsulated TLR9 agonist, CMP-001 [7] . CMP-001 is made up of a short piece of DNA that is packaged in a VLP. The DNA contained in CMP-001 activates the immune system and recruits cells of the immune system to the tumor. INCAGN01949 is an antibody-a type of protein-which has been shown to stimulate the immune system. Injecting both CMP-001 and INCAGN01949 would reduce tumor growth [10] . Further in vitro and in vivo studies are warranted in order to clarify the

Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System

The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment

VLPs Derived from the CCMV Plant Virus Can Directly Transfect and Deliver Heterologous Genes for Translation into Mammalian Cells

Major findings and recent advances in virus-like particle (VLP)-based vaccines

Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting

Immunity to α-Gal: Toward a Single-Antigen Pan-Vaccine to Control Major Infectious Diseases

Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against Leishmania Infection

The race for coronavirus vaccines: A graphical guide

Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19

CMP-001 and INCAGN01949 for Patients with Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license